Advancement and prospects of tumor gene therapy

Chinese Journal of Cancer

Volumn 30, Issue 3, 2011, Pages 182-188

  Zhang, Chao ^a   Wang, Qing Tao ^a   Liu, He ^a   Zhang, Zhen Zhu ^a   Huang, Wen Lin ^a,b  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Angiogenesis; Antisense RNA; Dendritic cells; Gene therapy; Non viral vector; Oxidative stress; RNA interference; Suicide gene; Tumor suppressor gene; Viral vector

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; INTERLEUKIN 12; LIPOSOME; MINICIRCLE DNA; NAKED DNA; NANOPARTICLE; VIRUS VECTOR;

ANTIANGIOGENIC GENE THERAPY; ANTISENSE THERAPY; ARTICLE; CANCER GENE THERAPY; CELL THERAPY; DENDRITIC CELL; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE TARGETING; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMMUNE RESPONSE; MICROBUBBLE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEIC ACID TRANSPORT; OXIDATIVE STRESS; RNA INTERFERENCE; SUICIDE GENE; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

EID: 79954565713     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.010.10074     Document Type: Article

References (77)

1. http://en.wikipedia.org/wiki/Gene_therapy.
2. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADASC ID: initial trial results after 4 years [J]. Science, 1995,270(5235):475-480.
3. Edelstein ML, Abedi MR, Wixon J, et al. Gene therapy clinical trials worldwide 19892004an overview [J]. J Gene Med, 2004,6 (6):597-602.
4. Cotrim AP, Baum BJ. Gene therapy: some history, applications, problems, and prospects [J]. Toxicol Pathology, 2008,36(1):97-103.
5. El-Aneed A. An overview of current delivery systems in cancer gene therapy [J]. J Control Release, 2004,94(1):1-14.
6. Kaneda Y, Tabata Y. Nonvi ral vectors for cancer therapy [J]. Cancer Sci, 2006,97(5):348-354.
7. Nie S, Xing Y, Kim GJ, et al. Nanotechnology applications in cancer [J]. Annu Rev Biomed Eng, 2007,9:257-288.
8. Bergen M, Chen R, Gonzalez R. Efficacy and safety of HLAB7 / beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma [J]. Expert Opin Biol Ther, 2003,3(2):377-384.
9. Yoshida J, Mizuno M, Fujii M, et al. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes [J]. Hum Gene Ther, 2004,15(1): 77-86.
10. Wang Y, Gao S, Ye WH, et al. Codelivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer [J]. Nat Mater, 2006,5(10):791-796.
11. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer [J]. Nat Rev Drug Discov, 2008,7(9):771-782.
12. Liang B, He ML, Chan CY, et al. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat [J]. Biomaterials, 2009,30(23-24):4014-4020.
13. Li C, Wallace S. Polymer-drug conjugates: recent development in clinical oncology [J]. Adv Drug Deliv Rev, 2008,60(8):886-898.
14. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies [J]. Adv Drug Deliv Rev, 2008,60(8):899-914.
15. Heller LC, Heller R. In vivo electroporation for gene therapy [J]. Hum Gene Ther, 2006,17(9):890-897.
16. Andre F, Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic applications [J]. Gene Ther, 2004,11(Suppl 1):S33-S42.
17. Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma [J]. J Clin Oncol, 2008,26(36):5896-5903.
18. Wells DJ. Electroporation and ultrasound enhanced non-viral gene delivery in vitro and in vivo [J]. Cell Biol Toxicol, 2010,26(1):21-28.
19. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors [J]. Adv Drug Deliv Rev, 2008,60(10):1193-1208.
20. Merk&Co. Whitehouse Station, NJ: http://www.merk.com.
21. Rome C, Couillaud F, Moonen CT. Spatial and temporal control of expression of therapeutic genes using heat shock protein promoters [J]. Methods, 2005,35(2):188-198.
22. Liu Y, Kon T, Li C, et al. High intensity focused ultrasound-induced gene activation in sublethally injured tumor cells in vitro [J]. J Acoust Soc Am, 2005,118(5):3328-3336.
23. Liu Y, Kon T, Li C, et al. High intensity focused ultrasound-induced gene activation in solid tumors [J]. J Acoust Soc Am, 2006,120(1): 492-501.
24. Haag P, Frauscher F, Gradl J, et al. Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours [J]. J Steroid Biochem Mol Biol, 2006,102(1-5):103-113.
25. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX015 with intravenous gemcitabine in unresectable pancreatic carcinoma [J]. Clin Cancer Res, 2003,9(2):555-561.
26. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA [J]. Gene Ther, 1999,6(7):1258-1266.
27. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations [J]. Proc Natl Acad Sci USA, 1993,90(24):11478-11482.
28. Darquet AM, Cameron B, Wils P, et al. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle [J]. Gene Ther, 1997,4(12):1341-1349.
29. Chen ZY, He CY, Ehrhardt A, et al. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo [J]. Mol Ther, 2003,8(3):495-500.
30. Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo [J]. Hum Gene Ther, 2005,16(1):126-131.
31. Bigger BW, Tolmachov O, Collombet JM, et al. An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and itochondrial gene therapy [J]. J Biol Chem, 2001,276(25):23018-23027.
32. Darquet AM, Rangara R, Kreiss P, et al. Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer [J]. Gene Ther, 1999,6(2):209-218.
33. Wu J, Xiao X, Zhao P, et al. Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma [J]. Clin Cancer Res, 2006,12(15):4702-4713.
34. http://www.sibiono.com/en/introduce.html.
35. Spitz FR, Nguyen D, Skibber JM, et al. Adenoviralmediated wild type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation [J]. Clin Cancer Res, 1996,2(10):1665-1671.
36. Wadhwa PD, Zielske SP, Roth JC, et al. Cancer gene therapy: scientific basis [J]. Annu Rev Med, 2002,53:437-452.
37. Altaner C. Prodrug cancer gene therapy [J]. Cancer Lett, 2008,270 (2):191-201.
38. Denny WA. Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy) [J]. J Biomed Biotechnol, 2003,2003(1): 48-70.
39. Marais R, Spooner RA, Stribbling SM, et al. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy [J]. Nat Biotechnol, 1997,15(13):1373-1377.
40. Gadi VK, Alexander SD, Kudlow JE, et al. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells [J]. Gene Ther, 2000,7(20):1738-1743.
41. Boucher PD, Ostruszka LJ, Murphy PJ, et al. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy [J]. Gene Ther, 2002,9(15):1023-1030.
42. Boucher PD, Ostruszka LJ, Shewach DS. Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea [J]. Cancer Res, 2000,60(6):1631-1636.
43. Dilber MS, Abedi MR, Christensson B, et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo [J]. Cancer Res, 1997,57(8):1523-1528.
44. ersano L, Crescenzi M, Indraccolo S. Antiangiogenic gene therapy of cancer: current status and future prospects [J]. Mol Aspects Med, 2007,28(1):87-114.
45. Li L, Liu RY, Huang JL, et al. Adenovirusm ediated intratumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma [J]. Int J Cancer, 2006,118(8):2064-2071.
46. Dougan M, Dranoff G. Immune therapy for cancer [J]. Annu Rev Immunol, 2009,27:83-117.
47. Anwer K, Barnes MN, Fewell J, et al. PhaseI clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer [J]. Gene Ther, 2009,17(3):360-369.
48. http://clinicaltrials.gov/ct2/show/NCT00406939.
49. Yoshikawa T, Kokura S, Tainaka K, et al. A novel cancer therapy based on oxygen radicals [J]. Cancer Res, 1995,55(8):1617-1620.
50. Huang P, Feng L, Oldham EA, et al. Superoxide dismutase as a target for the selective killing of cancer cells [J]. Nature, 2000,407(6802):390-395.
51. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation [J]. Adv Drug Deliv Rev, 2009,61(4):290-302.
52. Stegman LD, Zheng H, Neal ER, et al. Induction of cytotoxic oxidative stress by Dal anine in brain tumor cells expressing Rhodotorula gracilis D-am ino acid oxidase: a cancer gene therapy strategy [J]. Hum Gene Tther, 1998,9(2):185-193.
53. Fang J, Sawa T, Akaike T, et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor [J]. Cancer Res, 2003,63(13):3567-3574.
54. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference [J]. Nat Rev Genet, 2007,8(3):173-184.
55. Dykxhoorn DM, Chowdhury D, Lieberman J. RNA interference and cancer: endogenous pathways and therapeutic approaches [J]. Adv Exp Med Biol, 2008,615:299-329.
56. Check E. A crucial test [J]. Nature medicine, 2005,11(3):243-244.
57. Kim DH, Longo M, Han Y, et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase [J]. Nat Biotechnol, 2004,22(3):321-325.
58. Rossi JJ. RNAi as a treatment for HIV1 infection [J]. BioTechniques, 2006,40(S4):S25-S29.
59. Emmrich S, Wang W, John K, et al. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo [J]. Mol Cancer, 2009,8:61.
60. Zhao X, Pan F, Holt CM, et al. Controlled delivery of antisense oligonucleotides: a brief review of current strategies [J]. Expert Opin Drug Deliv, 2009,6(7):673-686.
61. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways [J]. Cell Res, 2006,16(2):141-147.
62. Martin SE, Caplen NJ. Applications of RNA interference in mammalian systems [J]. Ann Rev Genom Hum G, 2007,8:81-108.
63. Aboobaker AA, Tomancak P, Patel N, et al. Drosophila microRNAs exhibit diverse spatial expression patterns during embryonic development [J]. Proc Natl Acad Sci USA, 2005,102(50):18017-18022.
64. Biemar F, Zinzen R, Ronshaugen M, et al. Spatial regulation of microRNA gene expression in the Drosophila embryo [J]. Proc Natl Acad Sci USA, 2005,102(44):15907-15911.
65. Smits EL, Anguille S, Cools N, et al. Dendritic cellbased cancer gene therapy [J]. Hum Gene Ther, 2009,20(10):1106-1108.
66. Kyte JA, Gaudernack G. Immunogene therapy of cancer with tumour-mRNA transfected dendritic cells [J]. Cancer Immunol Immunother, 2006,55(11):1432-1442.
67. Schmitz V, Barajas M, Wang L, et al. Adenovirusmediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma [J]. Hepatology, 2001,34(1):72-81.
68. Robert C, Klein C, Cheng G, et al. Gene therapy to target dendritic cells from blood to lymph nodes [J]. Gene Ther, 2003,10 (17): 1479-1486.
69. Balkir L, Tourkova IL, Makarenkova VP, et al. Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivity to tumorinduced apoptosis [J]. J Gene Med, 2004,6(5):537-544.
70. June CH. Adoptive T cell therapy for cancer in the clinic [J]. J Clin Invest, 2007,117(6):1466-1476.
71. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen [J]. Blood, 2009,114(3): 535-546.
72. Schumacher TN. T-cell-receptor gene therapy [J]. Nat Rev Immunol, 2002,2(7):512-519.
73. Haynes NM, Snook MB, Trapani JA, et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCRzeta vs Fc epsilon RI-gamma [J]. J Immunol, 2001,166(1):182-187.
74. Randolph DA, Huang G, Carruthers CJ, et al. The role of CCR7 in TH1 and TH2 cell localization and delivery of B cell help in vivo [J]. Science, 1999,286(5447):2159-2162.
75. Evans LS, Witte PR, Feldhaus AL, et al. Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth [J]. Hum Gene Ther, 1999,10(12):1941-1951.
76. Bendle GM, Haanen JB, Schumacher TN. Preclinical development of T cell receptor gene therapy [J]. Curr Opin Immunol, 2009,21(2): 209-214.
77. Bos R, van Duikeren S, Morreau H, et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen [J]. Cancer Res, 2008,68 (20):8446-8455.